MA40901A - Anticorps bispécifiques anti-tnf/anti-il-3 - Google Patents

Anticorps bispécifiques anti-tnf/anti-il-3

Info

Publication number
MA40901A
MA40901A MA040901A MA40901A MA40901A MA 40901 A MA40901 A MA 40901A MA 040901 A MA040901 A MA 040901A MA 40901 A MA40901 A MA 40901A MA 40901 A MA40901 A MA 40901A
Authority
MA
Morocco
Prior art keywords
tnf
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
MA040901A
Other languages
English (en)
Inventor
Catherine B Beidler
Jr Rohn L Millican
Songqing Na
Neungseon Seo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA40901A publication Critical patent/MA40901A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA040901A 2014-11-05 2015-11-02 Anticorps bispécifiques anti-tnf/anti-il-3 MA40901A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462075571P 2014-11-05 2014-11-05

Publications (1)

Publication Number Publication Date
MA40901A true MA40901A (fr) 2017-09-12

Family

ID=54477413

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040901A MA40901A (fr) 2014-11-05 2015-11-02 Anticorps bispécifiques anti-tnf/anti-il-3

Country Status (9)

Country Link
US (1) US9718884B2 (fr)
EP (1) EP3215529A1 (fr)
JP (1) JP2017533705A (fr)
CN (1) CN108064249A (fr)
AR (1) AR102417A1 (fr)
CA (1) CA2959551C (fr)
MA (1) MA40901A (fr)
TW (1) TWI585105B (fr)
WO (1) WO2016073406A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368066A1 (fr) * 2015-10-30 2018-09-05 Eli Lilly and Company Anticorps bispécifiques anti-cgrp/anti-il-23 et leurs utilisations
AR111845A1 (es) * 2017-05-03 2019-08-28 Lilly Co Eli Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
CN108640997A (zh) * 2018-05-22 2018-10-12 蔡毓旻 一种双特异性抗体
KR102088789B1 (ko) * 2018-06-20 2020-03-13 인하대학교 산학협력단 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
JP7517999B2 (ja) 2018-11-27 2024-07-17 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 抗ＩＬ－２３ｐ１９抗体およびその使用
KR20220012883A (ko) * 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
IL293561A (en) * 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
BR112022022919A2 (pt) * 2020-05-13 2022-12-20 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".
BR112022023489A2 (pt) * 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
TW202428304A (zh) * 2020-09-10 2024-07-16 美商美國禮來大藥廠 治療性抗體調配物
CA3201564A1 (fr) * 2020-12-09 2022-06-16 Jung Min Yoo Anticorps anti-ox40l, anticorps bispecifique anti-ox40l/anti-tnfalpha et leurs utilisations
KR20250075632A (ko) * 2022-09-21 2025-05-28 인매진 피티이. 엘티디. TNFα 및 IL-23을 표적으로 하는 항체 및 이의 용도
WO2025024723A1 (fr) * 2023-07-26 2025-01-30 Sorriso Pharmaceuticals, Inc. Traitement par induction d'il-23 et de tnf-alpha pour des troubles auto-immuns et inflammatoires
WO2025076251A1 (fr) * 2023-10-05 2025-04-10 Sorriso Pharmaceuticals, Inc. Dosages d'inhibiteurs d'il-23 et de tnf-alpha destinés à être utilisés dans des troubles auto-immuns et inflammatoires
CN117534732B (zh) * 2023-11-03 2024-10-22 湖南中晟全肽生物科技股份有限公司 一种抑制il-12与其受体结合的多肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
KR20120091477A (ko) 1999-03-25 2012-08-17 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
MXPA05004512A (es) 2002-10-30 2005-07-26 Genentech Inc Inhibicion de la produccion de il-17.
WO2004058178A2 (fr) 2002-12-23 2004-07-15 Schering Corporation Utilisations de cytokine de mammifere et reactifs correspondants
JP4605798B2 (ja) 2003-03-10 2011-01-05 シェーリング コーポレイション Ｉｌ−２３アゴニストおよびｉｌ−２３アンタゴニスト；関連試薬の使用
TWI363091B (en) 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1937721B1 (fr) 2005-08-25 2010-07-28 Eli Lilly And Company Anticorps anti-il-23
HUE032131T2 (en) * 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
JP2009507023A (ja) * 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
EP3219328B1 (fr) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Compositions, procédés et utilisations d'anticorps humains anti-il-23
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
JP2010513245A (ja) * 2006-12-14 2010-04-30 アクトジェニックス・エヌブイ 免疫調節を誘起するための結合分子の送達
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
EP2064242A1 (fr) 2007-02-23 2009-06-03 Schering Corporation Anticorps obtenus par génie génétiques dirigés contre l'il-23p19
AU2008219681A1 (en) * 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
WO2009120922A2 (fr) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions et procédés pour inhiber pdgfr-bêta et vegf-a
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2010027766A1 (fr) 2008-08-27 2010-03-11 Schering Corporation Formulations lyophilisées d'anticorps anti-il-23p19 modifiés
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
EP2918602A1 (fr) 2009-04-16 2015-09-16 AbbVie Biotherapeutics Inc. Anticorps anti-TNF-alpha et leurs utilisations
WO2011017294A1 (fr) * 2009-08-07 2011-02-10 Schering Corporation Anticorps anti-rankl humain
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
SG184473A1 (en) * 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
US9127057B2 (en) 2010-07-20 2015-09-08 Teva Pharmaceuticals Ausralia Pty Ltd Anti-IL-23 heterodimer specific antibodies
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
US20140212425A1 (en) * 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP3594245A1 (fr) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigènes chimériques bispécifiques et leurs utilisations thérapeutiques
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
WO2013181585A2 (fr) * 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Méthodes associées à l'adalimumab
US20150322519A1 (en) 2012-12-21 2015-11-12 Joshua MICELWEE Biomarkers for psoriasis treatment response
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
TW201444867A (zh) 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
AU2014228553B2 (en) 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
US10059763B2 (en) * 2014-09-03 2018-08-28 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof

Also Published As

Publication number Publication date
EP3215529A1 (fr) 2017-09-13
CA2959551C (fr) 2018-09-11
WO2016073406A1 (fr) 2016-05-12
TWI585105B (zh) 2017-06-01
AR102417A1 (es) 2017-03-01
US9718884B2 (en) 2017-08-01
JP2017533705A (ja) 2017-11-16
TW201627321A (zh) 2016-08-01
CN108064249A (zh) 2018-05-22
US20160122429A1 (en) 2016-05-05
CA2959551A1 (fr) 2016-05-12

Similar Documents

Publication Publication Date Title
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
HUE051700T2 (hu) Anti-PD-1 antitestek
FR25C1022I1 (fr) Anticorps anti-pd-1
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
EP3334824A4 (fr) Anticorps anti-pd-1
DK3332006T5 (da) Hidtil ukendte anti-PD-L1-antistoffer
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3344654T3 (da) Anti-lag-3-antistoffer
SI3354729T1 (sl) Protitelesa anti-garp
EP3532489A4 (fr) Anticorps monoclonaux neutralisants anti-tl1a
PL3274366T3 (pl) Chimeryczny receptor antygenowy
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
IL256097A (en) Antibody epitope
EP3383915A4 (fr) Anticorps anti-pd-1
PL3215530T3 (pl) Ulepszone przeciwciała anty-il-6
EP3212232A4 (fr) Anticorps bispécifique tétravalent anti-tlr9
MA50222A (fr) Anticorps bispécifiques anti-pd-l1-anti-tim-3